Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000533069 | SCV000639875 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2024-05-27 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002438372 | SCV002745350 | uncertain significance | Inborn genetic diseases | 2019-10-28 | criteria provided, single submitter | clinical testing | The p.T899M variant (also known as c.2696C>T), located in coding exon 9 of the ATRX gene, results from a C to T substitution at nucleotide position 2696. The threonine at codon 899 is replaced by methionine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Natera, |
RCV000533069 | SCV002087325 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2019-10-28 | no assertion criteria provided | clinical testing |